Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [19] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [19] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [20] - Commercial expenses rose significantly to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [20] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024 [20] - Full-year net loss was $63.1 million or $0.75 per share, compared to $41.5 million or $0.67 per share in 2024 [21] Business Line Data and Key Metrics Changes - The launch of CARDAMYST is seen as a pivotal moment for the company, targeting over 2 million patients with PSVT, marking the first new therapeutic option in 30 years [4][5] - The commercial strategy focuses on driving new patient starts and achieving commercial coverage, with a sales force of approximately 60 representatives targeting around 10,000 providers [10] Market Data and Key Metrics Changes - The company has filed a marketing authorization application for CARDAMYST in Europe, with expectations for a decision in the first half of 2027 [7] - The company is actively engaging with payers to demonstrate the value proposition of CARDAMYST, aiming to reduce emergency department visits and hospital utilization [11] Company Strategy and Development Direction - The FDA approval of CARDAMYST is viewed as a foundation for value creation, with a focus on building a strong commercial franchise [5] - The company aims to leverage comprehensive clinical data to seek marketing approvals in other regions, enhancing the credibility of CARDAMYST [6] - The strategy includes ensuring a positive initial experience for patients and prescribers, with a focus on accessibility and affordability [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early feedback from prescribers and the initial launch of CARDAMYST, indicating strong demand generation [12][18] - The company anticipates prescription volume to increase and commercial coverage to expand over time, with more meaningful progress expected in the latter half of the year [18] Other Important Information - The company reported a pro forma estimated cash figure of $200 million, supporting the successful launch of CARDAMYST and providing an operating runway into late 2027 [7][22] - The leadership team has been enhanced with the addition of David Sandoval as General Counsel and Chief Compliance Officer [8] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted a broad mix of prescribers adopting CARDAMYST, including cardiologists and advanced practice providers, with coverage denials primarily due to paperwork requirements for patient eligibility [26][28] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks once the system is engaged, with ongoing efforts to support patients in accessing the drug during the delay period [32][35] Question: Current prescribing trends and patient mix - Management reported that CARDAMYST is being prescribed to a diverse patient group, including those awaiting ablation and those with existing medications, but emphasized that it is too early to identify specific trends [43][44] Question: Contracting strategy and formulary positioning - The company aims for broad access with reasonable coverage terms, targeting commercial plans first, with Medicare coverage expected to follow in 2027 [50][57]

Financial Data and Key Metrics Changes - In 2025, the company's revenue increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [20] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income [21] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22] - Administrative expenses were CNY 199.5 million, a decline of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and organizational optimization [23] - As of December 31, 2025, cash and cash equivalents were CNY 1,941 million, expected to support operations beyond 2028 [22] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV functional cure program, which remains its top clinical priority, with key data reported and studies progressing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][5] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, establishing labs in Beijing and Shanghai to support early-stage drug discovery [9][36] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a strategic approach to market engagement [32][38] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses to approximately one quarter of their original level [5] - The strategy includes a disciplined partnering approach for non-HBV assets while focusing on areas with the strongest near-term opportunities [10][11] - The company plans to introduce new programs from its discovery platform and define its development strategy around them [24][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, expecting important data to emerge later this year to inform the next stage of development [40] - The company is aware of the competitive landscape and aims to differentiate its offerings while exploring the potential of its expanded discovery capabilities [29][36] Other Important Information - The company has made significant investments in building its internal research capabilities and integrating AI-enabled discovery tools into its workflow [8][9] - The company is open to both internal development and partnerships for its discovery programs, depending on expertise and market potential [38] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in the ENRICH study, and a 10% or better response in the ENHANCE study compared to previous results [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is expanding beyond infectious diseases to include chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32]

Financial Data and Key Metrics Changes - The company reported full year 2025 revenues of EUR 1,917 million, a decrease of 1.5% year-over-year on a reported basis, but an increase of 1.1% on an organic basis [9] - Gross margin improved by 90 basis points to 67.5%, primarily driven by a shift in channel mix, with Direct-to-Consumer (DTC) sales reaching 82% of branded revenues compared to 78% the previous year [10] - Adjusted EBIT was EUR 163 million, which included EUR 10 million in provisions related to losses on trade receivables [9][10] - The company achieved a profit of EUR 109 million, up 20% from EUR 91 million the previous year [10] Business Line Data and Key Metrics Changes - The Zegna segment generated an adjusted EBIT of EUR 197 million with a margin of 14.4%, up from 13.9% the previous year [13] - The Thom Browne segment faced challenges, achieving only EUR 1 million in adjusted EBIT due to a reduction in revenues from wholesale streamlining [14] - The Tom Ford Fashion segment reported a loss of EUR 16 million in adjusted EBIT for the first half of the year, but showed improvement in the second half [14] Market Data and Key Metrics Changes - The Middle East region represents a mid-high single-digit share of the company's total revenues, with all stores in the area currently open and operating [18] - The company noted a cautious outlook for the Chinese market, expecting a flattish performance for the year despite some sequential improvement [27] Company Strategy and Development Direction - The company is focusing on enhancing its brand presence through high-profile fashion shows and collaborations, such as the Thom Browne sneaker launch with ASICS [4][5] - Zegna aims to build a brand that seamlessly integrates fashion, culture, and landscape, with plans for a spring/summer 2027 fashion show in Los Angeles [8] - The company is committed to long-term investments in talent, systems, and store network expansions, particularly for Thom Browne and Tom Ford [11] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the first quarter of 2026, noting a slight improvement in DTC trends compared to Q4 2025, despite uncertainties from the Middle East conflict [26] - The company remains focused on delivering its 2027 targets, acknowledging the increased uncertainty in the global economic outlook [19] Other Important Information - The effective tax rate decreased to 22% from 30% the previous year due to non-taxable income related to the remeasurement of put option liabilities [15] - The company plans to distribute a dividend of 12 cents per share, totaling approximately EUR 32 million [15] Q&A Session Summary Question: Update on top-line momentum and regional trends - Management noted that the year has started well, with trends slightly better than Q4 2025 in DTC, despite uncertainties from the Middle East conflict [26] Question: Zegna segment EBIT margin expectations - Management indicated that the Zegna segment's EBIT margin could improve, with a focus on long-term profitability rather than short-term results [29] Question: Impact of foreign exchange on profitability - Management acknowledged that currency fluctuations could create a headwind of around two points on profitability for 2026 [30] Question: Changes in consumer behavior due to recent events - Management reported no significant changes in consumer behavior outside the Middle East, where traffic has decreased [36] Question: Pricing environment and opportunities - Management confirmed ongoing low to mid-single-digit price increases and an upward evolution of the product mix [47] Question: Middle East market specifics - Management confirmed that the UAE is the largest market in the Middle East, with plans to continue store openings in the region [116]

Financial Data and Key Metrics Changes - XPeng achieved total revenues of CNY 22.25 billion for Q4 2025, representing a 38.2% year-over-year increase and a 9.2% quarter-over-quarter increase [34] - Vehicle sales revenues were CNY 19.07 billion for Q4 2025, up 30% year-over-year and 5.6% quarter-over-quarter, primarily due to higher deliveries [34] - Gross margin for Q4 2025 was 21.3%, compared to 14.4% in Q4 2024 and 20.1% in Q3 2025 [35] - Net profit for Q4 2025 was CNY 0.38 billion, marking the first positive net profit for a single quarter, compared to a net loss of CNY 1.33 billion year-over-year [38] Business Line Data and Key Metrics Changes - Annual delivery reached 42,945 units, a 126% increase year-over-year, with significant contributions from the MONA M03 and P7+ models [5] - Revenues from services and others were CNY 3.18 billion for Q4 2025, a 121.9% year-over-year increase, driven by technical R&D services to Volkswagen and increased parts sales [35] Market Data and Key Metrics Changes - Overseas deliveries nearly doubled to 45,000 units, contributing over 15% of total revenue [5] - The company aims to double overseas deliveries in 2026, targeting international business to contribute over 20% of total revenue [14] Company Strategy and Development Direction - XPeng plans to launch four new models in 2026, expanding into both large and compact vehicles, designed for global markets [11] - The company is focusing on enhancing its AI capabilities and aims to push the technological frontier in autonomous driving and smart cockpit systems [9] - XPeng's strategy includes significant investment in physical AI R&D, with a planned increase to CNY 7 billion in 2026 [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving fully autonomous driving capabilities within the next one to three years, with VLA 2.0 expected to enhance user experience and retention [10][48] - The company anticipates strong quarter-over-quarter growth in vehicle deliveries and revenue in 2026, driven by new model launches and technological advancements [31] Other Important Information - XPeng's cash position at the end of 2025 was CNY 47.66 billion, providing robust financial support for ongoing investments in AI R&D [38] - The company has established a full stack in-house developed technology system, including SoC and AI infrastructure, to support its autonomous driving initiatives [9] Q&A Session Summary Question: What type of major upgrade should we expect for XPeng's VLA 2.0 in the coming months? - Management expects at least one major version of OTA each quarter, with enhancements in road coverage and AI capabilities [42][44] Question: What is the deployment roadmap for XPeng Ultra model and VLA 2.0 in the overseas market? - VLA 2.0 testing is set to begin by the end of this year, with plans for gradual rollout in international markets [52] Question: What is the current progress of Robotaxi testing? - Management indicated that fully autonomous driving capability is expected within one to three years, with ongoing R&D for global operations [81]

Financial Data and Key Metrics Changes - XPeng achieved total revenues of RMB 22.25 billion for Q4 2025, representing a year-over-year increase of 38.2% and a quarter-over-quarter increase of 9.2% [32] - Vehicle sales revenues were RMB 19.07 billion for Q4 2025, up 30% year-over-year and 5.6% quarter-over-quarter, primarily due to higher deliveries [33] - Gross margin for Q4 2025 was 21.3%, compared to 14.4% in Q4 2024 and 20.1% in Q3 2025 [34] - Net profit for Q4 2025 was RMB 0.38 billion, marking the first positive net profit for a single quarter [37] Business Line Data and Key Metrics Changes - Annual delivery reached 42,945 units, a 126% increase year-over-year [5] - Revenues from services and others were RMB 3.18 billion for Q4 2025, up 121.9% year-over-year, driven by technical R&D services to Volkswagen and increased parts sales [34] Market Data and Key Metrics Changes - Overseas deliveries nearly doubled to 45,000 units, contributing over 15% of total revenue [5] - The company aims to double overseas deliveries in 2026, targeting international business to contribute over 20% of total revenue [13] Company Strategy and Development Direction - XPeng plans to launch four new models in 2026, expanding into both large and compact vehicles, designed for global markets [10] - The company is focusing on enhancing its AI capabilities and aims to push the technological frontier in autonomous driving and smart cockpit systems [8] - XPeng's strategy includes significant investment in physical AI R&D, with a planned increase to RMB 7 billion in 2026 [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant growth in the physical AI market, which is expected to surpass the automotive industry in the next 5-10 years [26] - The company anticipates that the VLA 2.0 will enhance user retention and conversion rates, with expectations of higher sales volumes [45] - Management highlighted the importance of addressing safety issues and weaknesses in their technology before scaling up operations globally [47] Other Important Information - XPeng's cash position at the end of 2025 was RMB 47.66 billion, providing strong financial support for ongoing investments [37] - The company has begun mass production of its Turing AI SoC and has shipped over 200,000 units [19] Q&A Session Summary Question: What type of major upgrade should we expect for XPeng's VLA 2.0 in the coming months? - Management expects at least one major version of OTA each quarter, with enhancements in autonomous driving capabilities and multi-language support [42][44] Question: What is the deployment roadmap for XPeng Ultra model and VLA 2.0 in the overseas market? - VLA 2.0 testing is set to begin by the end of this year, with plans for gradual rollout in international markets [52] Question: What are the key markets for achieving 100% volume growth overseas this year? - Europe and Southeast Asia are identified as key markets, with local production efforts underway to support growth [71][74] Question: What is the current progress of Robotaxi testing? - Management indicated that fully autonomous driving capability is expected in 1-3 years, with ongoing testing and regulatory compliance efforts [83]

Financial Data and Key Metrics Changes - The company reported full year 2025 revenues of EUR 1,917 million, a decrease of 1.5% year-over-year on a reported basis, but an increase of 1.1% on an organic basis [9] - Gross margin reached 67.5%, up 90 basis points, primarily driven by a shift in channel mix with Direct-to-Consumer (DTC) accounting for 82% of branded revenues compared to 78% the previous year [10] - Adjusted EBIT was EUR 163 million, which included EUR 10 million in provisions related to losses on trade receivables [9][10] - The company achieved a profit of EUR 109 million, a 20% increase from EUR 91 million in the previous year [10] - The effective tax rate decreased to 22% from 30% due to non-taxable income related to the remeasurement of put option liabilities [15] Business Line Data and Key Metrics Changes - The Zegna segment generated an adjusted EBIT of EUR 197 million with a margin of 14.4%, up from 13.9% the previous year [13] - The Thom Browne segment was significantly impacted by a reduction in revenues, achieving only EUR 1 million in adjusted EBIT [14] - The Tom Ford Fashion segment reported a loss of EUR 16 million in adjusted EBIT for the first half of the year, but showed improvement in the second half [14] Market Data and Key Metrics Changes - The Middle East region represents a mid-high single-digit share of the company's total revenues, with all stores in the area currently open and operating [18] - The Americas, particularly the United States and Latin America, showed resilience with continued growth, while Europe also remained stable despite the conflict in the Middle East [27] Company Strategy and Development Direction - The company is focusing on enhancing its brand presence through strategic collaborations, such as the Thom Browne sneaker launch with ASICS, which has exceeded revenue expectations [4][5] - Zegna aims to build a brand that integrates fashion, culture, and landscape, with upcoming events like the spring and summer 2027 fashion show in Los Angeles [8] - The company is committed to a long-term vision, investing in talent and infrastructure to support brand growth, particularly for Thom Browne and Tom Ford [11][29] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the current trends, noting slight improvements in DTC performance compared to Q4 2025, despite uncertainties from the Middle East conflict [26] - The company remains cautious about the Chinese market, expecting a flattish performance for the year while acknowledging slight improvements during the Chinese New Year [27] - Management highlighted the importance of maintaining strong relationships with customers in the Middle East and adapting strategies to the evolving market conditions [41] Other Important Information - The company plans to open new stores in Abu Dhabi by the end of the year, continuing its expansion strategy in the Middle East [116] - Capital expenditures for 2025 reached EUR 103 million, with expectations for increased investments in 2026 related to a new shoe factory [16] Q&A Session Summary Question: Update on top-line momentum and regional trends - Management noted that the year has started well with trends slightly better than Q4 2025, particularly in DTC, despite uncertainties from the Middle East conflict [26] Question: Zegna segment EBIT margin expectations - Management indicated that the Zegna segment's EBIT margin could improve, with a focus on long-term profitability rather than short-term results [29] Question: Impact of foreign exchange on profitability - Management acknowledged a potential headwind of around 2 points from currency fluctuations affecting profitability in 2026 [30] Question: Changes in consumer behavior due to the current environment - Management reported no significant changes in consumer behavior outside the Middle East, where traffic has decreased [36] Question: Pricing environment and opportunities for higher pricing - Management confirmed ongoing low to mid-single-digit price increases and an upward evolution of the product mix [47] Question: Shipment status and rent structure in the Middle East - Management confirmed that shipments to the Middle East are ongoing, with a mix of variable and fixed rents [62] Question: Profitability improvements for Tom Ford in H2 - Management highlighted improvements in gross margin and operational efficiency as key drivers for Tom Ford's profitability in the second half [64] Question: Exposure to local versus tourist spending - Management indicated that local spending is predominant, with minimal exposure to tourist spending, particularly in Greater China [68]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated total revenue of $475.6 million, an increase from $463.3 million in 2024, primarily driven by growth in cloud mining solutions, mining equipment sales, and hosting services [17][18] - The company recorded a net loss of $57.4 million in 2025, compared to a net income of $54 million in 2024, attributed to a larger non-cash impairment loss on mining equipment and increased unrealized fair value losses [24][25] - Adjusted EBITDA for the full year was $8.3 million, indicating positive operational performance despite the net loss [25] Business Line Data and Key Metrics Changes - Cloud mining business generated a record $350.6 million in 2025, up over 29% from $271 million in 2024, accounting for nearly 74% of total revenue [5][18] - Self-mining revenue decreased to $63.1 million in 2025 from $157.5 million in 2024, representing about 13% of total revenue compared to 34% in 2024 [19] - Mining equipment sales increased by 76.4% year-over-year to $53.7 million, driven by strong demand for the S21 series [23] Market Data and Key Metrics Changes - The company ended 2025 with 1,778 Bitcoins, an increase from 1,720 Bitcoins at the end of 2024, and continued to build its Bitcoin treasury into 2026, reaching 1,830 Bitcoins by February 28, 2026 [12][26] - The average cash cost to mine one Bitcoin was $77,573 in 2025, reflecting a blended cost structure across self-mining operations [20] Company Strategy and Development Direction - The company focuses on a hybrid model of cloud mining and self-mining, aiming to balance upside potential and operational resilience [9][10] - Strategic priorities for 2026 include scaling cloud mining, expanding managed capacity, improving reliability through the Aladdin system, optimizing capital allocation, and building the Bitcoin treasury [16][27] - The company aims to evaluate opportunities for expanding owned capacity, particularly in North America and the Middle East, while maintaining disciplined capital allocation [26][27] Management's Comments on Operating Environment and Future Outlook - The cryptocurrency industry faced challenges in 2025, particularly for mining enterprises, due to Bitcoin price volatility, which created cash flow pressures for many participants [4][5] - The management believes that the current market environment presents opportunities for growth, particularly in acquiring infrastructure and expanding customer bases during market dips [15][16] - The company maintains a conservative debt profile and liquidity management strategy to navigate through market cycles [12][27] Other Important Information - The company successfully onboarded additional suppliers and diversified its hash rate supply to mitigate risks associated with supplier concentration [7] - The net dollar retention rate was 100% in 2025, indicating strong customer loyalty despite market fluctuations [11] Q&A Session Summary Question: Why are some customers willing to pay a premium for cloud mining services instead of buying Bitcoin directly? - Customers benefit from dollar cost averaging and cost visibility, allowing systematic exposure to Bitcoin over time [27][28] - Financial leverage through installment payments enables customers to invest more in hash rate rather than upfront Bitcoin purchases [28] - Cloud mining offers dynamic output based on network conditions, providing potential for higher returns compared to direct purchases [28][29] - Institutional customers prefer cloud mining for operational revenue recognition and compliance with stringent regulations [29][30]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents, restricted cash, and fixed-term deposits amounted to $211 million, a decrease of $53 million from $264 million as of December 31, 2024, primarily due to cash payments and operational expenses [20][21] - The company reported a consolidated net loss attributable to shareholders for the twelve months ended December 31, 2025, with specific figures available in the press release [21] Business Line Data and Key Metrics Changes - The allogeneic CAR-T candidate lasme-cel achieved a 100% overall response rate in the target phase 2 population, converting all patients to transplant-eligible candidates [6][13] - The dual CAR-T candidate eti-cel demonstrated an 88% overall response rate and a 63% complete response rate in heavily pre-treated patients [9][16] Market Data and Key Metrics Changes - Cellectis is advancing its pivotal phase 2 trial for lasme-cel, with site openings in North America and Europe expected to continue into 2026 [8] - The company is also collaborating with partners like Servier and Allogene, with key milestones anticipated in 2026 [19] Company Strategy and Development Direction - Cellectis aims to transform into a late-stage development organization, focusing on delivering clinical results for patients with no therapeutic solutions [4][11] - The company is committed to internalizing its manufacturing capabilities, which has shown improved efficacy compared to external manufacturing [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position to fund operations into the second half of 2027, allowing for continued development of lasme-cel and eti-cel [18] - The management highlighted the importance of their allogeneic CAR-T products in addressing unmet medical needs in oncology, particularly for patients with aggressive diseases [4][6] Other Important Information - The anticipated BLA submission for lasme-cel is planned for the second half of 2028, while eti-cel is expected to progress to pivotal phase 2 in 2027 with a BLA submission in H2 2029 [16] - The company is actively engaging in partnerships to enhance its gene editing platform and expand its product offerings [10][11] Q&A Session Summary Question: Update on lasme-cel and BALLI-01 enrollment - Management confirmed that recruitment is on track and expects to complete data analysis by the end of the year for the first 40 patients [24] Question: Expectations for dose optimization in the pivotal study - Management indicated that they anticipate being able to differentiate between the two dose levels of alemtuzumab based on efficacy and safety [25] Question: Details on Servier arbitration and its impact - The arbitration ruling allowed Cellectis to regain rights to UCART19, while remaining eligible for milestones related to cema-cel [30] Question: Importance of alemtuzumab in lymphodepletion - Management emphasized that alemtuzumab is critical for optimizing lymphodepletion and achieving better patient outcomes [33] Question: Update on esiCell and patient follow-up - Management provided a top-line update indicating strong complete remission rates and plans for further data sharing by the end of the year [37] Question: Application of lymphodepletion in outpatient settings - Management noted that regulatory requirements currently necessitate inpatient delivery, but there is potential for future outpatient use [58] Question: AstraZeneca partnership updates - Management expressed satisfaction with the collaboration but indicated that updates would be limited at AstraZeneca's request due to competitive considerations [60]

Financial Data and Key Metrics Changes - The company reported full year 2025 revenues of EUR 1,917 million, a decrease of 1.5% year-over-year on a reported basis, but an increase of 1.1% on an organic basis [10] - Gross margin improved by 90 basis points to 67.5%, primarily driven by a shift in channel mix, with Direct-to-Consumer (DTC) sales reaching 82% of branded revenues compared to 78% the previous year [11] - Adjusted EBIT was EUR 163 million, which included EUR 10 million in provisions related to losses on trade receivables [10][11] - The company achieved a profit of EUR 109 million, up 20% from EUR 91 million the previous year [11][15] - The effective tax rate decreased to 22% from 30% due to non-taxable income related to the remeasurement of put option liabilities [15] Business Line Data and Key Metrics Changes - The Zegna segment generated an adjusted EBIT of EUR 197 million with a margin of 14.4%, up from 13.9% the previous year [13] - The Thom Browne segment was significantly impacted by a reduction in revenues, achieving only EUR 1 million in adjusted EBIT [14] - The Tom Ford Fashion segment reported a loss of EUR 16 million in adjusted EBIT for the year, with EUR 5 million in provisions related to Saks Global [14] Market Data and Key Metrics Changes - The Middle East region represents a mid-high single-digit share of the company's total revenues, with all stores in the area currently open and operating [18] - The company noted that the Americas and Europe remain resilient despite the conflict in the Middle East, with good growth expected [26] Company Strategy and Development Direction - The company is focusing on enhancing its brand presence through cultural initiatives, such as sponsoring the Italian Pavilion at the Venice Biennale [8] - Future plans include the launch of new collections and collaborations, such as the Thom Browne sneaker with ASICS, aimed at attracting new customers [5][6] - The company is committed to a long-term vision, emphasizing the importance of brand heritage and customer experience [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the current operating environment, noting slight improvements in DTC trends and performance in various regions, particularly in the Americas and Europe [25][26] - The company remains cautious about the Chinese market, expecting a flattish performance for the year despite some signs of improvement [25][26] - Management acknowledged the uncertainty in the global economic outlook due to geopolitical factors, particularly in the Middle East [19] Other Important Information - The company plans to increase capital expenditures (CapEx) to approximately 7% of revenues in 2026, primarily for the new shoe factory in Parma [16] - Trade working capital improved to EUR 408 million, representing 21.3% of revenues, down from 23.6% the previous year [17] Q&A Session Summary Question: Update on top-line momentum and regional trends - Management noted that the year has started well, with trends slightly better than Q4 2025 in DTC, despite uncertainties from the Middle East conflict [25][26] Question: Zegna segment EBIT margin expectations - Management indicated that the Zegna segment's EBIT margin could improve, with a focus on long-term profitability rather than short-term results [28] Question: Impact of foreign exchange on profitability - Management acknowledged a potential headwind of around 2 points from currency fluctuations affecting profitability [29] Question: Changes in consumer behavior and spending - Management reported no significant changes in consumer behavior outside the Middle East, where traffic has decreased [36] Question: Profitability improvements for Tom Ford and Thom Browne - Management expects profitability for both brands to improve in 2026, with Thom Browne aiming for a return to reasonable profitability [101]

Financial Data and Key Metrics Changes - XPeng's total revenues for Q4 2025 were RMB 22.25 billion, an increase of 38.2% year-over-year and 9.2% quarter-over-quarter [32] - Vehicle sales revenue was RMB 19.07 billion, up 30% year-over-year and 5.6% quarter-over-quarter, primarily due to higher deliveries [32] - Gross margin for Q4 2025 was 21.3%, compared to 14.4% in Q4 2024 and 20.1% in Q3 2025 [33] - Net profit for Q4 2025 was RMB 0.38 billion, marking the first positive net profit for a single quarter [36] Business Line Data and Key Metrics Changes - Annual delivery reached 42,945 units, a 126% increase year-over-year [5] - Revenues from services and others were RMB 3.18 billion, representing a 121.9% year-over-year increase [33] - Vehicle margin for Q4 2025 was 13%, up from 10% in Q4 2024 [34] Market Data and Key Metrics Changes - Overseas deliveries nearly doubled to 45,000 units, contributing over 15% of total revenue [5] - The company aims to double overseas deliveries in 2026, targeting international business to contribute over 20% of total revenue [13] Company Strategy and Development Direction - XPeng plans to launch four new models in 2026, expanding into both large and compact vehicles [11] - The company is focusing on enhancing its global market share and expanding its AI vehicle offerings [12] - XPeng's strategy includes significant investment in R&D, with CNY 9.5 billion allocated in 2025, including CNY 4.5 billion for AI [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant growth in the physical AI market, which is expected to surpass the automotive industry in the next 5-10 years [26] - The company anticipates that the VLA 2.0 will enhance user retention and conversion rates, with expectations of higher sales volume [44] - Management highlighted the importance of addressing safety issues and weaknesses in their technology before global deployment [46] Other Important Information - XPeng's cash position as of December 31, 2025, was RMB 47.66 billion, providing robust financial support for ongoing investments [36] - The company has begun construction of a humanoid robot mass production base in Guangzhou, targeting over 1,000 units per month by the end of 2026 [25] Q&A Session Summary Question: What type of major upgrade should we expect for XPeng's VLA 2.0 in the coming months? - Management indicated that they expect at least one major version of OTA each quarter, with significant improvements in autonomous driving capabilities [40][41] Question: What is the deployment roadmap for XPeng Ultra model and VLA 2.0 in the overseas market? - Management confirmed that VLA 2.0 testing is underway, with plans for gradual rollout in international markets by the end of the year [48][50] Question: What are the key markets for achieving 100% volume growth overseas this year? - Europe and Southeast Asia were identified as key markets, with local production efforts underway to support growth [67][70] Question: What is the current progress of Robotaxi testing? - Management stated that fully autonomous driving capability is expected to be achieved in 1-3 years, with ongoing testing and regulatory compliance efforts [78]